Profile data is unavailable for this security.
About the company
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. Its lead program, Elraglusib Injection, is an intravenous solution of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib Injection has been evaluated in a Phase I dose escalation study (Actuate-1801 Part 1) in 238 adult patients. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2015
- Employees11.00
- LocationActuate Therapeutics Inc1751 RIVER RUN, SUITE 400FORT WORTH 76107United StatesUSA
- Phone+1 (847) 986-4190
- Websitehttps://actuatetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gossamer Bio Inc | 105.32m | -71.65m | 157.83m | 135.00 | -- | 2.92 | -- | 1.50 | -0.3283 | -0.3283 | 0.4595 | 0.2389 | 0.3014 | -- | -- | 780,162.90 | -20.51 | -57.43 | -23.67 | -64.38 | -- | -- | -68.03 | -- | -- | -6.84 | 0.7847 | -- | -- | -- | 21.61 | -- | -- | -- |
2Seventy Bio Inc | 45.62m | -94.55m | 160.16m | 274.00 | -- | 0.7023 | -- | 3.51 | -1.85 | -1.85 | 0.8659 | 4.43 | 0.0797 | -- | 2.18 | 166,496.30 | -16.52 | -- | -18.31 | -- | 65.72 | 91.76 | -207.25 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Checkpoint Therapeutics Inc | 47.00k | -46.47m | 165.05m | 23.00 | -- | -- | -- | 3,511.78 | -1.44 | -1.44 | 0.0013 | -0.2749 | 0.0127 | -- | -- | 2,043.48 | -1,256.40 | -142.43 | -- | -342.79 | -- | -- | -98,868.09 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
Actuate Therapeutics Inc | -100.00bn | -100.00bn | 167.58m | 11.00 | -- | 31.27 | -- | -- | -- | -- | -- | 0.2744 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0703 | -- | -- | -- | -22.74 | -- | -- | -- |
Verastem Inc | 10.00m | -93.45m | 168.68m | 73.00 | -- | 13.80 | -- | 16.87 | -3.18 | -3.18 | 0.3311 | 0.8002 | 0.0661 | -- | 100.00 | 136,986.30 | -61.78 | -62.70 | -77.44 | -75.18 | -- | -- | -934.54 | -406.17 | -- | -- | 0.5579 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
Greenwich Lifesciences Inc | 0.00 | -10.50m | 168.91m | 3.00 | -- | 33.90 | -- | -- | -0.8111 | -0.8111 | 0.00 | 0.3791 | 0.00 | -- | -- | 0.00 | -140.17 | -36.43 | -151.72 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Heron Therapeutics Inc | 137.74m | -27.97m | 169.87m | 126.00 | -- | -- | -- | 1.23 | -0.1841 | -0.1841 | 0.9067 | -0.2637 | 0.6122 | 0.871 | 2.11 | 1,093,151.00 | -12.43 | -53.55 | -19.65 | -71.24 | 72.19 | 52.52 | -20.30 | -170.12 | 1.74 | -- | 1.36 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Adaptimmune Therapeutics PLC - ADR | 175.04m | -44.52m | 169.99m | 449.00 | -- | 2.12 | -- | 0.9712 | -0.2126 | -0.2126 | 0.7109 | 0.3128 | 0.5701 | -- | 26.34 | 389,846.30 | -14.50 | -41.19 | -18.73 | -48.21 | -- | -- | -25.43 | -714.26 | 3.82 | -- | 0.384 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
DiaMedica Therapeutics Inc | 0.00 | -21.71m | 171.85m | 18.00 | -- | 3.58 | -- | -- | -0.5527 | -0.5527 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -39.23 | -45.38 | -41.66 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0055 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
Galectin Therapeutics Inc | 0.00 | -45.23m | 175.31m | 14.00 | -- | -- | -- | -- | -0.7284 | -0.7284 | 0.00 | -1.48 | 0.00 | -- | -- | 0.00 | -176.31 | -92.08 | -587.13 | -121.97 | -- | -- | -- | -- | -- | -7.18 | 8.66 | -- | -- | -- | -15.26 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -117.23m | 175.87m | 140.00 | -- | 1.56 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Nkarta Inc | 0.00 | -110.61m | 176.42m | 159.00 | -- | 0.4095 | -- | -- | -1.87 | -1.87 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -23.59 | -32.39 | -24.86 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Caribou Biosciences Inc | 11.48m | -148.12m | 177.48m | 158.00 | -- | 0.6312 | -- | 15.47 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Kyverna Therapeutics Inc | 0.00 | -110.66m | 177.77m | 119.00 | -- | 0.5875 | -- | -- | -2.50 | -2.50 | 0.00 | 7.01 | 0.00 | -- | -- | 0.00 | -51.27 | -- | -57.66 | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -96.49m | 179.23m | 59.00 | -- | 2.16 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Holder | Shares | % Held |
---|---|---|
AWM Investment Co., Inc.as of 30 Sep 2024 | 139.51k | 0.71% |
Long Corridor Asset Management Ltd.as of 30 Sep 2024 | 125.00k | 0.64% |
RBC Capital Markets LLC (Investment Management)as of 30 Sep 2024 | 35.30k | 0.18% |
Geode Capital Management LLCas of 30 Sep 2024 | 27.89k | 0.14% |
Northwestern University (Investment Management)as of 30 Sep 2024 | 27.78k | 0.14% |
KG&L Capital Management LLCas of 30 Sep 2024 | 12.00k | 0.06% |
Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2024 | 10.97k | 0.06% |
Wells Fargo Clearing Services LLCas of 30 Sep 2024 | 3.39k | 0.02% |
Tower Research Capital LLCas of 30 Sep 2024 | 297.00 | 0.00% |
Bank of America, NA (Private Banking)as of 30 Sep 2024 | 23.00 | 0.00% |